Fulgent Genetics, Inc. Common Stock
FLGTStock
$20.55+16.27%52W
Market Cap$588.46M
P/E—
Div yield—
Beta0.90
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.45%
Price vs S&P 500 (4W)16.19%
VGM Score41.70
Market Capitalization$588.46M
Earnings Surprise History
Q1 26-0.36est. -0.11
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
2.17
2.17
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FLGTFulgent Genetics, Inc. Common Stock | C | D | C | $20.55 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| VCYTVeracyte, Inc. | D | A | A | $59.22 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
About
Fulgent Genetics is a genetic testing company providing physicians with diagnostic laboratory services and clinical interpretation to guide patient treatment. The company's core laboratory services segment, which generates the majority of revenue, offers technical testing and professional interpretation by licensed physicians. The company also operates a therapeutic development business focused on developing cancer drug candidates, with operations primarily in the United States and select international markets.